EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm

Arya Mariam Roy iD, Vasanthan Muthusamy Kumarasamy, Ajay Dhakal iD, Ruth O'Regan iD, Shipra Gandhi iD

Cancer · 15.09.2023 · 129 (18) · 2773-2788

DOI: 10.1002/cncr.34904 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 22.06.2023. Verfasst von Arya Mariam Roy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)‐status to HER2‐low, defined as HER2 expression of 1+ by immunohistochemistry (IHC) or 2+ by IHC without gene amplification, has made a major impact in the field of oncology. The HER2‐low expression has emerged as a targetable biomarker, and anti‐HER2 antibody‐drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2‐low breast cancer (BC). With these recent data, the treatment algorithm for hormone receptor–positive and triple‐negative BC needs to be reconsidered, as approximately half of these BCs are HER2‐low. Although there are different therapeutic agents for hormone receptor–positive and hormone receptor–negative HER2‐low BCs, there is no consensus regarding the sequencing of these agents. In this article, the treatment options for HER2‐low BC are enumerated and a treatment sequencing algorithm based on the current clinical evidence proposed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsImmunoconjugatesHumansFemaleTrastuzumabErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

HER2-low breast cancerPARP inhibitorsalpelisibeverolimushormone receptor negative HER2-lowhormone receptor-positive HER2-lowsacituzumab govitecantrastuzumab deruxtecan

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsImmunoconjugates

Autor:innen und Institutionen

  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Department of Medicine, University at Buffalo, Buffalo, New York, USA.
  • Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.

ORCID-Profile: Arya Mariam Roy, Ajay Dhakal, Ruth O'Regan, Shipra Gandhi

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Roy, A. M., Kumarasamy, V. M., Dhakal, A., O'Regan, R., & Gandhi, S. (2023). A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm. Cancer, 129(18), 2773-2788. https://doi.org/10.1002/cncr.34904

Vancouver

Roy AM, Kumarasamy VM, Dhakal A, O'Regan R, Gandhi S. A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm. Cancer. 2023;129(18):2773-2788. doi:10.1002/cncr.34904

BibTeX
@article{Roy2023,
  author = {Roy, Arya Mariam and Kumarasamy, Vasanthan Muthusamy and Dhakal, Ajay and O'Regan, Ruth and Gandhi, Shipra},
  title = {A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {18},
  pages = {2773--2788},
  doi = {10.1002/cncr.34904}
}
Kostenlos starten →